ArcherDx Joins Canadian Personalized Oncology Consortium | GenomeWeb

NEW YORK (GenomeWeb) – Contextual Genomics and the Personalized Medicine Initiative today announced that ArcherDx has joined the Canadian National Access Project for Cancer Testing.

ArcherDx's gene fusion assays will be used to help identify lung cancer gene mutations, Contextual Genomics CEO Chris Wagner said in a statement. ArcherDx's FusionPlex technology can detect EML4-ALK gene fusions and will "enhance our cancer panel tests to identify this mutated gene fusion in lung cancer patients," he said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Startup companies are taking on personalized medicine, CNET reports.

Bruce Booth writes at Life Sci VC that biotech clusters like Boston and San Francisco are getting even more consolidated.

The Verge speaks with Mark and Scott Kelly, who are the subjects of NASA's Twin Study.

In Genome Biology this week: genes linked to Hirschsprung disease, structural variant patterns in autism, and more.